Dexcom
DXCMDXCM · Stock Price
Historical price data
Overview
Dexcom is a pioneering medical device company with a mission to empower people to take control of their health through innovative continuous glucose monitoring (CGM) technology. Founded in 1999, the company has achieved a dominant position in the diabetes care market with its best-in-class G7 systems and is now strategically expanding into the metabolic health space with its OTC Stelo biosensor. With a market cap of $24.44B, Dexcom's strategy leverages relentless product innovation, a robust payer coverage network, and a growing ecosystem of digital health partnerships to drive sustained growth.
Technology Platform
Proprietary continuous glucose monitoring platform utilizing a glucose oxidase enzyme-based sensor, wireless transmitter, and a comprehensive digital ecosystem for real-time data display, analytics, and third-party integration.
Pipeline
4| Drug | Indication | Stage | Watch |
|---|---|---|---|
| Afrezza Inhalant Product | Type 2 Diabetes Treated With Insulin | Approved | |
| verapamil 120mg tablet + placebo | Type1 Diabetes | Phase 3 | |
| Sotagliflozin + Placebo | Diabetic Nephropathies | Phase 3 | |
| Mini-glucagon | Type 1 Diabetes | Pre-clinical |
Funding History
2Company Timeline
Founded in San Diego, United States
Initial Public Offering
Debt: $500.0M